MX2010006854A - Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina. - Google Patents

Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.

Info

Publication number
MX2010006854A
MX2010006854A MX2010006854A MX2010006854A MX2010006854A MX 2010006854 A MX2010006854 A MX 2010006854A MX 2010006854 A MX2010006854 A MX 2010006854A MX 2010006854 A MX2010006854 A MX 2010006854A MX 2010006854 A MX2010006854 A MX 2010006854A
Authority
MX
Mexico
Prior art keywords
biomarkers
sensitivity
methods
igf1r
therapy
Prior art date
Application number
MX2010006854A
Other languages
English (en)
Inventor
Yan Wang
Yaolin Wang
Ming Liu
Cynthia Seidel-Dugan
Diane Levitan
Wei Ding
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010006854A publication Critical patent/MX2010006854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Theoretical Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona, por ejemplo, métodos para determinar convenientemente si una condición cancerosa en un sujeto será sensible a un inhibidor de IGF1R; la invención incluye métodos de selección de paciente y métodos de tratamiento.
MX2010006854A 2007-12-18 2008-12-17 Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina. MX2010006854A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1455607P 2007-12-18 2007-12-18
US1593807P 2007-12-21 2007-12-21
US2290908P 2008-01-23 2008-01-23
PCT/US2008/087240 WO2009079587A2 (en) 2007-12-18 2008-12-17 Biomarkers for sensitivity to anti-igf1r therapy

Publications (1)

Publication Number Publication Date
MX2010006854A true MX2010006854A (es) 2010-09-09

Family

ID=40796133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006854A MX2010006854A (es) 2007-12-18 2008-12-17 Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.

Country Status (6)

Country Link
US (1) US20110091524A1 (es)
EP (1) EP2247757A2 (es)
JP (2) JP2011505873A (es)
CA (1) CA2709827A1 (es)
MX (1) MX2010006854A (es)
WO (1) WO2009079587A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
TW200803892A (en) 2005-11-04 2008-01-16 Wyeth Corp Antineoplastic combinations with MTOR inhibitor, herceptin, and/or HKI-272
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
NZ590464A (en) 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
NZ597692A (en) 2008-12-12 2013-08-30 Boehringer Ingelheim Int Anti-IGF antibodies
KR20160106211A (ko) 2009-04-06 2016-09-09 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
AP3083A (en) * 2009-11-18 2015-01-31 Helsinn Healthcare Sa Compositions for treating centrally mediated nausea and vomiting
WO2011066200A1 (en) * 2009-11-30 2011-06-03 Merck Sharp & Dohme Corp. Methods for the identification and treatment of patients sensitive to anti igf-1r inhibition therapy
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012175481A1 (en) * 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
WO2014059196A2 (en) * 2012-10-10 2014-04-17 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of sma and smn deficiency
CA2890658A1 (en) 2012-11-09 2014-05-15 The Johns Hopkins University A genetic assay to determine prognosis in polycythemia vera patients
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
MX2016002547A (es) 2013-08-28 2016-06-17 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones.
BR112016018891A2 (pt) * 2014-02-21 2017-10-10 Abbvie Stemcentrx Llc anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CN110231482B (zh) * 2014-08-26 2022-07-19 学校法人庆应义塾 抗癌剂的感受性的判定标记
US20170372347A1 (en) * 2016-06-22 2017-12-28 International Business Machines Corporation Sequence-based marketing attribution model for customer journeys
JP2020529870A (ja) * 2017-08-10 2020-10-15 ザ インスティチュート オブ キャンサー リサーチ，ロイヤル キャンサー ホスピタル がんを層別化し、処置するための材料及び方法
CN107714719A (zh) * 2017-11-08 2018-02-23 上海市第妇婴保健院 雷帕霉素在制备治疗白细胞介素‑27低表达子宫内膜癌的药物中的应用
CN111394462A (zh) * 2020-04-13 2020-07-10 浙江大学 一种肝癌索拉非尼耐药circRNA标志物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856094A (en) * 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US5989885A (en) * 1997-01-10 1999-11-23 Myriad Genetics, Inc. Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
NZ554740A (en) * 2002-05-24 2009-01-31 Schering Corp Neutralizing human anti-IGFR antibody
US7378503B2 (en) * 2003-04-02 2008-05-27 Hoffmann-La Roche Inc. Antibodies against insulin-like growth factor 1 receptor and uses thereof
BRPI0417302A (pt) * 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
MX2007006640A (es) * 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
WO2006113483A2 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
DK1926996T3 (da) * 2005-09-20 2012-01-23 Osi Pharmaceuticals Llc Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere
US7875274B2 (en) * 2005-12-16 2011-01-25 The Board Of Trustees Of The Leland Stanford Junior University Protein modulators of resistance to alkylating agents
JP5399900B2 (ja) * 2006-06-30 2014-01-29 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｇｆｂｐ２インヒビター
WO2008076278A2 (en) * 2006-12-13 2008-06-26 Schering Corporation Methods of cancer treatment with igf1r inhibitors
WO2008144345A2 (en) * 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

Also Published As

Publication number Publication date
EP2247757A2 (en) 2010-11-10
WO2009079587A3 (en) 2009-11-12
CA2709827A1 (en) 2009-06-25
WO2009079587A2 (en) 2009-06-25
JP2011505873A (ja) 2011-03-03
US20110091524A1 (en) 2011-04-21
JP2013078341A (ja) 2013-05-02

Similar Documents

Publication Publication Date Title
MX2010006854A (es) Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
PH12021550758A1 (en) The use of inhibitors of bruton`s tyrosine kinase (btk)
WO2010017515A3 (en) Breast cancer specific markers and methods of use
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
WO2008103645A3 (en) Prostate cancer and melanoma antigens
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
HK1108284A1 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
EA201490230A1 (ru) Применение меченых ингибиторов hsp90
MX2010008496A (es) Metodo para la determinacion de sensibilidad a agente anticancerigeno.
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2011015602A3 (en) Lung cancer biomarkers
IN2012DN03817A (es)
TW200639404A (en) Method of assessing the effectiveness of a treatment regimen
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
MX2010010393A (es) Uso de la catepsina c.
MX2012000509A (es) Biomarcador para seleccionar pacientes y metodos relacionados.
WO2010015538A3 (en) Predictive marker for egfr inhibitor treatment
GB2465907A (en) VHZ for diagnosis and treatment of cancer
WO2011011453A3 (en) Phenotyping tumor-infiltrating leukocytes
UA95956C2 (uk) Набір для визначення mage-а3
WO2007081777A3 (en) METHODS FOR ACCURATELY MEASURING FREE IgE IN THE PRESENCE OF AN ANTI-IgE THERAPEUTIC
MX2010001582A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001578A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Legal Events

Date Code Title Description
HC Change of company name or juridical status